Kendall Capital Management Makes New $87,000 Investment in Bausch Health Companies Inc. (NYSE:BHC)

Kendall Capital Management acquired a new stake in shares of Bausch Health Companies Inc. (NYSE:BHC) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 12,550 shares of the company’s stock, valued at approximately $87,000.

A number of other large investors also recently modified their holdings of BHC. Inspire Investing LLC purchased a new stake in Bausch Health Companies in the first quarter worth approximately $935,000. Norges Bank bought a new stake in shares of Bausch Health Companies in the 4th quarter worth approximately $31,121,000. Vanguard Group Inc. boosted its stake in shares of Bausch Health Companies by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 11,599,131 shares of the company’s stock valued at $93,025,000 after purchasing an additional 111,363 shares in the last quarter. Blair William & Co. IL grew its holdings in shares of Bausch Health Companies by 5.0% during the 1st quarter. Blair William & Co. IL now owns 84,245 shares of the company’s stock valued at $894,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Prudential PLC purchased a new position in Bausch Health Companies in the 4th quarter worth $735,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $6.21, for a total transaction of $83,027.70. Following the transaction, the executive vice president now owns 435,198 shares in the company, valued at approximately $2,702,579.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.12% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

BHC has been the topic of a number of recent research reports. Scotiabank reduced their price objective on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating on the stock in a research note on Friday, August 2nd. Truist Financial lowered their price objective on Bausch Health Companies from $8.00 to $7.00 and set a “hold” rating for the company in a research report on Thursday, July 25th. Royal Bank of Canada dropped their price objective on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a research note on Friday, August 2nd. StockNews.com downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Tuesday. Finally, Jefferies Financial Group dropped their price target on shares of Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.33.

Bausch Health Companies Stock Up 2.1 %

Shares of BHC stock opened at $8.19 on Friday. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -6.60 and a beta of 0.75. The stock has a fifty day moving average of $6.25 and a 200 day moving average of $7.35. Bausch Health Companies Inc. has a 52 week low of $3.96 and a 52 week high of $11.46.

Bausch Health Companies (NYSE:BHC) last posted its earnings results on Thursday, August 1st. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.89 by $0.09. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.33 billion. During the same period last year, the company posted $0.81 EPS. Equities research analysts anticipate that Bausch Health Companies Inc. will post 3.61 earnings per share for the current year.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.